Literature DB >> 31567595

Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey.

Rhiannon Bath1, Tanner Bucholz, Amy F Buros, Darshan Singh, Kirsten E Smith, Charles A Veltri, Oliver Grundmann.   

Abstract

OBJECTIVES: To determine whether diagnosed pre-existing health conditions correlate with Kratom demographics and use patterns.
METHODS: A cross-sectional, anonymous US national online survey was conducted among 8049 Kratom users in October, 2016 to obtain demographic, health, and Kratom use pattern information.
RESULTS: People who use Kratom to mitigate illicit drug dependence self-reported less pain and better overall health than individuals who used Kratom for acute/chronic pain. Self-reported improvements in pre-existing mental health symptoms (attention deficit and hyperactivity disorder/attention deficit disorder, anxiety, bipolar disorder, post-traumatic stress disorder, and depression) attributed to Kratom use were greater than those related to somatic symptoms (back pain, rheumatoid arthritis, acute pain, chronic pain, fibromyalgia). Demographic variables, including female sex, older age, employment status, and insurance coverage correlated with increased likelihood of Kratom use.
CONCLUSIONS: Kratom use may serve as a self-treatment strategy for a diverse population of patients with pre-existing health diagnoses. Healthcare providers need to be engaging with patients to address safety concerns and potential limitations of its use in clinical practice for specific health conditions.

Entities:  

Mesh:

Year:  2020        PMID: 31567595      PMCID: PMC7446542          DOI: 10.1097/ADM.0000000000000570

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   4.647


  39 in total

1.  A study of kratom eaters in Thailand.

Authors:  S Suwanlert
Journal:  Bull Narc       Date:  1975 Jul-Sep

Review 2.  Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons.

Authors:  Stephan Steidl; David I Wasserman; Charles D Blaha; John S Yeomans
Journal:  Neurosci Biobehav Rev       Date:  2017-09-23       Impact factor: 8.989

3.  Patterns of Kratom use and health impact in the US-Results from an online survey.

Authors:  Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2017-05-10       Impact factor: 4.492

4.  Characterization and consequences of pain variability in individuals with fibromyalgia.

Authors:  Richard E Harris; David A Williams; Samuel A McLean; Ananda Sen; Michael Hufford; R Michael Gendreau; Richard H Gracely; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2005-11

5.  Dopamine is differentially involved in the locomotor hyperactivity produced by manipulations of opioid, GABA and glutamate receptors in the median raphe nucleus.

Authors:  Insop Shim; Thomas R Stratford; David Wirtshafter
Journal:  Behav Brain Res       Date:  2013-12-12       Impact factor: 3.332

6.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

7.  Anti-inflammatory and antinociceptive effects of Mitragyna speciosa Korth methanolic extract.

Authors:  W M Shaik Mossadeq; M R Sulaiman; T A Tengku Mohamad; H S Chiong; Z A Zakaria; M L Jabit; M T H Baharuldin; D A Israf
Journal:  Med Princ Pract       Date:  2009-07-31       Impact factor: 1.927

8.  Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.

Authors:  Darshan Singh; Christian P Müller; Vikneswaran Murugaiyah; Shahrul Bariyah Sahul Hamid; Balasingam K Vicknasingam; Bonnie Avery; Nelson Jeng Yeou Chear; Sharif Mahsufi Mansor
Journal:  J Ethnopharmacol       Date:  2017-12-15       Impact factor: 4.360

Review 9.  Fibromyalgia.

Authors:  Sangita Chakrabarty; Roger Zoorob
Journal:  Am Fam Physician       Date:  2007-07-15       Impact factor: 3.292

10.  Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice.

Authors:  Kamini Vijeepallam; Vijayapandi Pandy; Thubasni Kunasegaran; Dharmani D Murugan; Murali Naidu
Journal:  Front Pharmacol       Date:  2016-12-06       Impact factor: 5.810

View more
  12 in total

1.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

2.  Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample.

Authors:  Jeffrey M Rogers; Kirsten E Smith; Justin C Strickland; David H Epstein
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 3.  [Kratom - a short review for pain medicine].

Authors:  Florian Lautenschlager; Manfred Weiss; Sigrun Feuerer; Norbert Wodarz
Journal:  Schmerz       Date:  2021-09-17       Impact factor: 1.629

4.  When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.

Authors:  Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein
Journal:  Am J Drug Alcohol Abuse       Date:  2021-04-28       Impact factor: 3.912

Review 5.  The Potential for Kratom as an Antidepressant and Antipsychotic.

Authors:  Lindsay E Johnson; Lilian Balyan; Amy Magdalany; Fizza Saeed; Robert Salinas; Starla Wallace; Charles A Veltri; Marc T Swogger; Zach Walsh; Oliver Grundmann
Journal:  Yale J Biol Med       Date:  2020-06-29

6.  Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study.

Authors:  Antonio Metastasio; Elisabeth Prevete; Darshan Singh; Oliver Grundmann; Walter C Prozialeck; Charles Veltri; Giuseppe Bersani; Ornella Corazza
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

Review 7.  Understanding Kratom Use: A Guide for Healthcare Providers.

Authors:  Marc T Swogger; Kirsten E Smith; Albert Garcia-Romeu; Oliver Grundmann; Charles A Veltri; Jack E Henningfield; Lorna Y Busch
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

8.  Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Kelly E Dunn; Oliver Grundmann; Christopher R McCurdy; Destiny Schriefer; David H Epstein
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

9.  Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Destiny Schriefer; Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

Review 10.  A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.

Authors:  Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-07-26       Impact factor: 2.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.